

**GASTROENTEROLOGY**

**PAPER-III**

GASTRO/D/19/10/III

Time: 3 hours  
Max. Marks:100

**Important Instructions:**

- Attempt all questions in order.
- Each question carries 10 marks.
- Read the question carefully and answer to the point neatly and legibly.
- Do not leave any blank pages between two answers.
- Indicate the question number correctly for the answer in the margin space.
- Answer all the parts of a single question together.
- Start the answer to a question on a fresh page or leave adequate space between two answers.
- Draw table/diagrams/flowcharts wherever appropriate.

**Write short notes on:**

1. a) Staging of Hepatocellular Carcinoma (HCC). 3+3+4  
b) Post TACE syndrome.  
c) Recent advances in systemic therapy in HCC.
2. a) Minimal hepatic encephalopathy (MHE) - definition. 2+3+5  
b) Tests for diagnosis of MHE.  
c) Management of MHE.
3. a) Normal gut flora. 3+4+3  
b) Indications for Fecal Microbiota Transplantation (FMT).  
c) Complications of FMT.
4. a) WHO classification of Primary tumours of the Exocrine Pancreas. 3+3+4  
b) Resectability in Carcinoma Pancreas.  
c) Management of unresectable Carcinoma Pancreas.
5. a) Lifestyle changes in management of NAFLD. 3+3+4  
b) Newer drugs in NAFLD treatment.  
c) Genetics of NAFLD.
6. a) Clinical features of Whipple's disease. 3+3+4  
b) Diagnosis of Whipple's disease.  
c) Management of Whipple's disease.
7. a) Types of Lumen apposing metallic stents in GI practice. 3+4+3  
b) Indications for Lumen apposing metallic stents.  
c) Complications of Lumen apposing metallic stents.
8. a) Surveillance in post colectomy Familial Adenomatous Polyposis syndrome patients. 5+5  
b) Chemoprevention of Colorectal Carcinoma.

P.T.O

**GASTROENTEROLOGY**

**PAPER-III**

- |     |  |       |
|-----|--|-------|
| 9.  | a) Transient elastography in NAFLD.                        | 3+4+3 |
|     | b) Noninvasive serum markers for fibrosis of liver.        |       |
|     | c) Indications for liver biopsy in NAFLD.                  |       |
| 10. | a) Biosimilar in Gastroenterology practice.                | 4+3+3 |
|     | b) Various formulations of mesalamine.                     |       |
|     | c) Therapeutic drug monitoring for Anti TNF agents in IBD. |       |

\*\*\*\*\*